Regulus Therapeutics Inc.

NASDAQ: RGLS · Real-Time Price · USD
8.16
0.00 (0.00%)
At close: Jun 24, 2025, 3:59 PM

Regulus Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
38.53M 23.77M 24.23M 60.38M
Short-Term Investments
37.25M n/a 14.93M n/a
Long-Term Investments
n/a n/a n/a n/a
Other Long-Term Assets
n/a n/a n/a 291K
Receivables
n/a n/a n/a n/a
Inventory
n/a 3.01M 3.01K 3.01K
Other Current Assets
3.08M 62K 62K 62K
Total Current Assets
82.34M 28.18M 44.08M 65.23M
Property-Plant & Equipment
1.81M 2.54M 2.58M 2.85M
Goodwill & Intangibles
25K 33K 62K 83K
Total Long-Term Assets
1.84M 2.57M 2.64M 3.22M
Total Assets
84.18M 30.75M 46.72M 68.45M
Account Payables
947K 204K 175K 285K
Deferred Revenue
n/a n/a n/a -589K
Short-Term Debt
n/a 1.33M 4.51M n/a
Other Current Liabilities
5.04M 5.36M 2.55M 1.29M
Total Current Liabilities
7.5M 8.51M 11.66M 5.23M
Long-Term Debt
n/a n/a n/a 4.67M
Other Long-Term Liabilities
n/a n/a n/a 1.18M
Total Long-Term Liabilities
274K 1.05M 1.77M 8.27M
Total Liabilities
7.77M 9.56M 13.43M 13.5M
Total Debt
274K 2.39M 6.28M 7.09M
Common Stock
66K 20K 17K 146K
Retained Earnings
-559.57M -513.21M -483.18M -454.85M
Comprehensive Income
50K n/a -12K n/a
Shareholders Equity
76.41M 21.19M 33.29M 54.96M
Total Investments
37.25M n/a 14.93M n/a